Cargando…

Translating preventive chemotherapy prevalence thresholds for Schistosoma mansoni from the Kato-Katz technique into the point-of-care circulating cathodic antigen diagnostic test

BACKGROUND: Intervention guidelines against Schistosoma mansoni are based on the Kato-Katz technique. However, Kato-Katz thick smears show low sensitivity, especially for light-intensity infections. The point-of-care circulating cathodic antigen (POC-CCA) is a promising rapid diagnostic test detecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Bärenbold, Oliver, Garba, Amadou, Colley, Daniel G., Fleming, Fiona M., Haggag, Ayat A., Ramzy, Reda M. R., Assaré, Rufin K., Tukahebwa, Edridah M., Mbonigaba, Jean B., Bucumi, Victor, Kebede, Biruck, Yibi, Makoy S., Meité, Aboulaye, Coulibaly, Jean T., N’Goran, Eliézer K., Tchuem Tchuenté, Louis-Albert, Mwinzi, Pauline, Utzinger, Jürg, Vounatsou, Penelope
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310297/
https://www.ncbi.nlm.nih.gov/pubmed/30550594
http://dx.doi.org/10.1371/journal.pntd.0006941
_version_ 1783383414781509632
author Bärenbold, Oliver
Garba, Amadou
Colley, Daniel G.
Fleming, Fiona M.
Haggag, Ayat A.
Ramzy, Reda M. R.
Assaré, Rufin K.
Tukahebwa, Edridah M.
Mbonigaba, Jean B.
Bucumi, Victor
Kebede, Biruck
Yibi, Makoy S.
Meité, Aboulaye
Coulibaly, Jean T.
N’Goran, Eliézer K.
Tchuem Tchuenté, Louis-Albert
Mwinzi, Pauline
Utzinger, Jürg
Vounatsou, Penelope
author_facet Bärenbold, Oliver
Garba, Amadou
Colley, Daniel G.
Fleming, Fiona M.
Haggag, Ayat A.
Ramzy, Reda M. R.
Assaré, Rufin K.
Tukahebwa, Edridah M.
Mbonigaba, Jean B.
Bucumi, Victor
Kebede, Biruck
Yibi, Makoy S.
Meité, Aboulaye
Coulibaly, Jean T.
N’Goran, Eliézer K.
Tchuem Tchuenté, Louis-Albert
Mwinzi, Pauline
Utzinger, Jürg
Vounatsou, Penelope
author_sort Bärenbold, Oliver
collection PubMed
description BACKGROUND: Intervention guidelines against Schistosoma mansoni are based on the Kato-Katz technique. However, Kato-Katz thick smears show low sensitivity, especially for light-intensity infections. The point-of-care circulating cathodic antigen (POC-CCA) is a promising rapid diagnostic test detecting antigen output of living worms in urine and results are reported as trace, 1+, 2+, and 3+. The use of POC-CCA for schistosomiasis mapping, control, and surveillance requires translation of the Kato-Katz prevalence thresholds into POC-CCA relative treatment cut-offs. Furthermore, the infection status of egg-negative but antigen-positive individuals and the intensity-dependent sensitivity of POC-CCA should be estimated to determine its suitability for verification of disease elimination efforts. METHODOLOGY: We used data from settings in Africa and the Americas characterized by a wide range of S. mansoni endemicity. We estimated infection intensity-dependent sensitivity and specificity of each test at the unit of the individual, using a hierarchical Bayesian egg-count model that removes the need to define a ‘gold’ standard applied to data with multiple Kato-Katz thick smears and POC-CCA urine cassette tests. A simulation study was carried out based on the model estimates to assess the relation of the two diagnostic tests for different endemicity scenarios. PRINCIPAL FINDINGS: POC-CCA showed high specificity (> 95%), and high sensitivity (> 95%) for moderate and heavy infection intensities, and moderate sensitivity (> 75%) for light infection intensities, and even for egg-negative but antigen-positive infections. A 10% duplicate slide Kato-Katz thick smear prevalence corresponded to a 15–40% prevalence of ≥ trace-positive POC-CCA, and 10–20% prevalence of ≥ 1+ POC-CCA. The prevalence of ≥ 2+ POC-CCA corresponded directly to single slide Kato-Katz prevalence for all prevalence levels. CONCLUSIONS/SIGNIFICANCE: The moderate sensitivity of POC-CCA, even for very light S. mansoni infections where the sensitivity of Kato-Katz is very low, and the identified relationship between Kato-Katz and POC-CCA prevalence thresholds render the latter diagnostic tool useful for surveillance and initial estimation of elimination of S. mansoni. For prevalence below 10% based on a duplicate slide Kato-Katz thick smear, we suggest using POC-CCA including trace results to evaluate treatment needs and propose new intervention thresholds that need to be validated in different settings.
format Online
Article
Text
id pubmed-6310297
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-63102972019-01-08 Translating preventive chemotherapy prevalence thresholds for Schistosoma mansoni from the Kato-Katz technique into the point-of-care circulating cathodic antigen diagnostic test Bärenbold, Oliver Garba, Amadou Colley, Daniel G. Fleming, Fiona M. Haggag, Ayat A. Ramzy, Reda M. R. Assaré, Rufin K. Tukahebwa, Edridah M. Mbonigaba, Jean B. Bucumi, Victor Kebede, Biruck Yibi, Makoy S. Meité, Aboulaye Coulibaly, Jean T. N’Goran, Eliézer K. Tchuem Tchuenté, Louis-Albert Mwinzi, Pauline Utzinger, Jürg Vounatsou, Penelope PLoS Negl Trop Dis Research Article BACKGROUND: Intervention guidelines against Schistosoma mansoni are based on the Kato-Katz technique. However, Kato-Katz thick smears show low sensitivity, especially for light-intensity infections. The point-of-care circulating cathodic antigen (POC-CCA) is a promising rapid diagnostic test detecting antigen output of living worms in urine and results are reported as trace, 1+, 2+, and 3+. The use of POC-CCA for schistosomiasis mapping, control, and surveillance requires translation of the Kato-Katz prevalence thresholds into POC-CCA relative treatment cut-offs. Furthermore, the infection status of egg-negative but antigen-positive individuals and the intensity-dependent sensitivity of POC-CCA should be estimated to determine its suitability for verification of disease elimination efforts. METHODOLOGY: We used data from settings in Africa and the Americas characterized by a wide range of S. mansoni endemicity. We estimated infection intensity-dependent sensitivity and specificity of each test at the unit of the individual, using a hierarchical Bayesian egg-count model that removes the need to define a ‘gold’ standard applied to data with multiple Kato-Katz thick smears and POC-CCA urine cassette tests. A simulation study was carried out based on the model estimates to assess the relation of the two diagnostic tests for different endemicity scenarios. PRINCIPAL FINDINGS: POC-CCA showed high specificity (> 95%), and high sensitivity (> 95%) for moderate and heavy infection intensities, and moderate sensitivity (> 75%) for light infection intensities, and even for egg-negative but antigen-positive infections. A 10% duplicate slide Kato-Katz thick smear prevalence corresponded to a 15–40% prevalence of ≥ trace-positive POC-CCA, and 10–20% prevalence of ≥ 1+ POC-CCA. The prevalence of ≥ 2+ POC-CCA corresponded directly to single slide Kato-Katz prevalence for all prevalence levels. CONCLUSIONS/SIGNIFICANCE: The moderate sensitivity of POC-CCA, even for very light S. mansoni infections where the sensitivity of Kato-Katz is very low, and the identified relationship between Kato-Katz and POC-CCA prevalence thresholds render the latter diagnostic tool useful for surveillance and initial estimation of elimination of S. mansoni. For prevalence below 10% based on a duplicate slide Kato-Katz thick smear, we suggest using POC-CCA including trace results to evaluate treatment needs and propose new intervention thresholds that need to be validated in different settings. Public Library of Science 2018-12-14 /pmc/articles/PMC6310297/ /pubmed/30550594 http://dx.doi.org/10.1371/journal.pntd.0006941 Text en © 2018 Bärenbold et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Bärenbold, Oliver
Garba, Amadou
Colley, Daniel G.
Fleming, Fiona M.
Haggag, Ayat A.
Ramzy, Reda M. R.
Assaré, Rufin K.
Tukahebwa, Edridah M.
Mbonigaba, Jean B.
Bucumi, Victor
Kebede, Biruck
Yibi, Makoy S.
Meité, Aboulaye
Coulibaly, Jean T.
N’Goran, Eliézer K.
Tchuem Tchuenté, Louis-Albert
Mwinzi, Pauline
Utzinger, Jürg
Vounatsou, Penelope
Translating preventive chemotherapy prevalence thresholds for Schistosoma mansoni from the Kato-Katz technique into the point-of-care circulating cathodic antigen diagnostic test
title Translating preventive chemotherapy prevalence thresholds for Schistosoma mansoni from the Kato-Katz technique into the point-of-care circulating cathodic antigen diagnostic test
title_full Translating preventive chemotherapy prevalence thresholds for Schistosoma mansoni from the Kato-Katz technique into the point-of-care circulating cathodic antigen diagnostic test
title_fullStr Translating preventive chemotherapy prevalence thresholds for Schistosoma mansoni from the Kato-Katz technique into the point-of-care circulating cathodic antigen diagnostic test
title_full_unstemmed Translating preventive chemotherapy prevalence thresholds for Schistosoma mansoni from the Kato-Katz technique into the point-of-care circulating cathodic antigen diagnostic test
title_short Translating preventive chemotherapy prevalence thresholds for Schistosoma mansoni from the Kato-Katz technique into the point-of-care circulating cathodic antigen diagnostic test
title_sort translating preventive chemotherapy prevalence thresholds for schistosoma mansoni from the kato-katz technique into the point-of-care circulating cathodic antigen diagnostic test
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310297/
https://www.ncbi.nlm.nih.gov/pubmed/30550594
http://dx.doi.org/10.1371/journal.pntd.0006941
work_keys_str_mv AT barenboldoliver translatingpreventivechemotherapyprevalencethresholdsforschistosomamansonifromthekatokatztechniqueintothepointofcarecirculatingcathodicantigendiagnostictest
AT garbaamadou translatingpreventivechemotherapyprevalencethresholdsforschistosomamansonifromthekatokatztechniqueintothepointofcarecirculatingcathodicantigendiagnostictest
AT colleydanielg translatingpreventivechemotherapyprevalencethresholdsforschistosomamansonifromthekatokatztechniqueintothepointofcarecirculatingcathodicantigendiagnostictest
AT flemingfionam translatingpreventivechemotherapyprevalencethresholdsforschistosomamansonifromthekatokatztechniqueintothepointofcarecirculatingcathodicantigendiagnostictest
AT haggagayata translatingpreventivechemotherapyprevalencethresholdsforschistosomamansonifromthekatokatztechniqueintothepointofcarecirculatingcathodicantigendiagnostictest
AT ramzyredamr translatingpreventivechemotherapyprevalencethresholdsforschistosomamansonifromthekatokatztechniqueintothepointofcarecirculatingcathodicantigendiagnostictest
AT assarerufink translatingpreventivechemotherapyprevalencethresholdsforschistosomamansonifromthekatokatztechniqueintothepointofcarecirculatingcathodicantigendiagnostictest
AT tukahebwaedridahm translatingpreventivechemotherapyprevalencethresholdsforschistosomamansonifromthekatokatztechniqueintothepointofcarecirculatingcathodicantigendiagnostictest
AT mbonigabajeanb translatingpreventivechemotherapyprevalencethresholdsforschistosomamansonifromthekatokatztechniqueintothepointofcarecirculatingcathodicantigendiagnostictest
AT bucumivictor translatingpreventivechemotherapyprevalencethresholdsforschistosomamansonifromthekatokatztechniqueintothepointofcarecirculatingcathodicantigendiagnostictest
AT kebedebiruck translatingpreventivechemotherapyprevalencethresholdsforschistosomamansonifromthekatokatztechniqueintothepointofcarecirculatingcathodicantigendiagnostictest
AT yibimakoys translatingpreventivechemotherapyprevalencethresholdsforschistosomamansonifromthekatokatztechniqueintothepointofcarecirculatingcathodicantigendiagnostictest
AT meiteaboulaye translatingpreventivechemotherapyprevalencethresholdsforschistosomamansonifromthekatokatztechniqueintothepointofcarecirculatingcathodicantigendiagnostictest
AT coulibalyjeant translatingpreventivechemotherapyprevalencethresholdsforschistosomamansonifromthekatokatztechniqueintothepointofcarecirculatingcathodicantigendiagnostictest
AT ngoraneliezerk translatingpreventivechemotherapyprevalencethresholdsforschistosomamansonifromthekatokatztechniqueintothepointofcarecirculatingcathodicantigendiagnostictest
AT tchuemtchuentelouisalbert translatingpreventivechemotherapyprevalencethresholdsforschistosomamansonifromthekatokatztechniqueintothepointofcarecirculatingcathodicantigendiagnostictest
AT mwinzipauline translatingpreventivechemotherapyprevalencethresholdsforschistosomamansonifromthekatokatztechniqueintothepointofcarecirculatingcathodicantigendiagnostictest
AT utzingerjurg translatingpreventivechemotherapyprevalencethresholdsforschistosomamansonifromthekatokatztechniqueintothepointofcarecirculatingcathodicantigendiagnostictest
AT vounatsoupenelope translatingpreventivechemotherapyprevalencethresholdsforschistosomamansonifromthekatokatztechniqueintothepointofcarecirculatingcathodicantigendiagnostictest